Table 1. Baseline characteristics of study patients.
| Variable | Combination therapy group (n=186) | Sorafenib group (n=90) | P value |
|---|---|---|---|
| Sex (M/F) | 167/19 | 73/17 | 0.045 |
| Age (years) | 54 (45–63) | 52 (47–64) | 0.308 |
| Age (<60/≥60) | 123/63 | 66/24 | 0.227 |
| HBsAg (P/N) | 161/25 | 80/10 | 0.586 |
| ALT level (U/L) | 45 (29–76) | 42 (27–73) | 0.629 |
| AST level (U/L) | 56 (39–78) | 58 (44–81) | 0.393 |
| Albumin (g/L) | 41.3 (36.2–44.1) | 40.6 (37.2–43.6) | 0.151 |
| Bilirubin (μmol/L) | 17.9 (12.6–21.0) | 16.5 (12.1–20.6) | 0.435 |
| Platelet count (×109/L) | 186 (136–248) | 192 (141–237) | 0.846 |
| AFP level (≤400/>400) | 104/82 | 43/47 | 0.204 |
| Child-Pugh score (A5/A6/B7) | 126/46/14 | 62/21/7 | 0.968 |
| Tumor number (1/2–3/≥4) | 97/51/38 | 48/21/21 | 0.725 |
| Tumor size (cm) | 7.1 (4.2–9.8) | 7.6 (4.7–9.6) | 0.343 |
| BUN (μmol/L) | 5.2 (4.1–7.3) | 4.9 (4.2–6.8) | 0.252 |
| Cr (μmol/L) | 63.2 (57.6–76.8) | 65.7 (53.6–78.2) | 0.497 |
| INR | 1.08 (1.02–1.13) | 1.09 (1.03–1.12) | 0.090 |
AFP, alpha fetoprotein; ALBI, Albumin-Bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; SD, standard deviation; BUN, blood urea nitrogen; Cr, creatinine.